Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).

José Alejandro Pérez Fidalgo,Alfonso Cortés Salgado,Y. García,Maria Iglesias,Uriel Bohn-Sarmiento,Elisa Calvo Garcia,Luis Manso Sánchez,Ana Santaballa,Ana Oaknin,Andrés Redondo,M.J. Rubio,Antonio González-Martín,Grupo Español de Investigación en Cáncer de Ovario

Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).

2021

José Alejandro Pérez Fidalgo
Alfonso Cortés Salgado
Y. García
Maria Iglesias
Uriel Bohn-Sarmiento
Elisa Calvo Garcia
Luis Manso Sánchez
Ana Santaballa
Ana Oaknin
Andrés Redondo
M.J. Rubio
Antonio González-Martín
Grupo Español de Investigación en Cáncer de Ovario

5549Background: The prognosis for patients with platinum-resistant/refractory ovarian cancer (PROC) is poor, and the aim of treatment is focused primarily on symptom control and maintenance of QoL....

Keywords:

platinum resistant
Refractory
Oncology
Internal medicine
Medicine
health related quality of life
Ovarian cancer
Pegylated Liposomal Doxorubicin
Clinical trial
symptom control
Olaparib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations